La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Resonance Health Bilan de santé

Santé financière contrôle des critères 6/6

Resonance Health has a total shareholder equity of A$9.8M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$10.9M and A$1.1M respectively.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$5.90m
Fonds propres	AU$9.84m
Total du passif	AU$1.08m
Total des actifs	AU$10.92m

Mises à jour récentes de la santé financière

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Mar 12

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Aug 19

Recent updates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Mar 12

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Aug 19

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Mar 01

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Jan 15

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Nov 22

Analyse de la situation financière

Passif à court terme: RHT's short term assets (A$7.3M) exceed its short term liabilities (A$889.7K).

Passif à long terme: RHT's short term assets (A$7.3M) exceed its long term liabilities (A$193.7K).

Historique et analyse du ratio d'endettement

Niveau d'endettement: RHT is debt free.

Réduire la dette: RHT has not had any debt for past 5 years.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: RHT has sufficient cash runway for more than 3 years based on its current free cash flow.

Prévisions de trésorerie: RHT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 31.8% each year

Resonance Health Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Recent updates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

New minor risk - Share price stability

New minor risk - Share price stability

Resonance Health Limited, Annual General Meeting, Nov 16, 2023

Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in FY 2022)

New minor risk - Financial data availability

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)

Resonance Health Ltd Announces That It Has Lodged Provisional Patent Application in Relation to an Invention for the Detection and Assessment of Fibrosis in the Liver and Other Organ

Insufficient new directors

Resonance Health Limited, Annual General Meeting, Nov 24, 2022

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

FerriScan Now Available on 3 Tesla (3T) MRI Machines

Resonance Health Limited Appoints Liesl Ellies as Joint Company Secretary

Insufficient new directors

Resonance Health Limited Receives United States CPT Code Confirmation for Liversmart

Resonance Health Limited Announces US FDA Clearance for LiverSmart

Resonance Health Ltd Provides Update on its Antisense Oligonucleotide Project for Treating Viral Hepatitis

Resonance Health Limited Announces Filing of Two Patent Applications

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Resonance Health Ltd announces R&D Molecular Medicine ASON Project Results of Dosing Study

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Chief Executive Officer Alison Laws has left the company

Resonance Health Limited Announces Filing of Patent Application

Resonance Health Limited Provides Update on Its Antisense Oligonucleotide R&D Project for Treating Liver Related Diseases

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Resonance Health Ltd HepaFat-AI Receives CE Marking

Resonance Health Ltd Receives Australian Therapeutic Goods Administration Approval for HepaFat-AI

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Resonance's HepaFat-AI Incorporated into Blackford Analysis

New 90-day high: AU$0.28

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Resonance Health Ltd Develops New Artificial Intelligence Tool for the Automated Review of Chest Computed Tomography Scans of Patients with Suspected Pulmonary Embolism

Full year earnings released - AU$0.0017 loss per share

Full year earnings released - AU$0.0017 loss per share

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines